...Biota Holdings Ltd. 's acquisition of MaxThera Inc. and Prolysis Ltd. fills some holes in its pipeline...
...its facilities in Oxford, U.K., and will offer Prolysis founder Jeff Errington a board seat. MaxThera...
...eligible for 12% of upfront and milestone payments if Biota out-licenses MaxThera's two main programs. MaxThera...

...Holdings Ltd. (ASX:BTA) gained A$0.03 to $2.68 last week after acquiring fellow infectious disease companies MaxThera Inc....
...receive A$10.8 million ($10 million) in Biota stock, for a 2.2% stake in Biota, while MaxThera...

...Biota acquired fellow infectious disease companies MaxThera and Prolysis. Prolysis shareholders will receive A$10.8 million ($10...
...all upfront and milestone payments received by Biota if Biota out-licenses MaxThera's two main programs. MaxThera...
...of Medicinal Chemistry Roger Frechette, both founders of MaxThera, will continue the programs at the MaxThera...

...Biota Holdings Ltd. (ASX:BTA) acquired fellow infectious disease companies MaxThera Inc. (Boston, Mass.) and Prolysis Ltd. (Yarnton...
...receive A$10.8 million ($10 million) in Biota stock, or a 2.2% stake in Biota, while MaxThera...
...to 15% of all milestones and royalties received by Biota should Prolysis' programs be out-licensed. MaxThera...